Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young children

Pediatric Infectious Disease Journal

Volumn 26, Issue 5, 2007, Pages 387-392

  Scheifele, David W ^a,d   Halperin, Scott A ^b   Ochnio, Jan J ^a   Mozel, Michelle ^a   Duarte Monteiro, Denzyl ^c   Wortzman, David ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Wyeth Pharmaceuticals Canada   (Canada)

^d BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Childhood; Immunization; Streptococcus pneumoniae

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; PENTACEL; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARM MOVEMENT; ARTICLE; BACTERIAL COLONIZATION; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SEROTYPE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN REDNESS; STREPTOCOCCUS INFECTION;

ANTIBODIES, BACTERIAL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MENINGOCOCCAL VACCINES; TIME FACTORS;

EID: 34249013412     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000259955.66171.0c     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and young children. Morb Mort Wk Rep. 2000;49(RR-9):1-35.
2. National Advisory Committee on Immunization. Statement on recommended use of pneumococcal conjugate vaccine. Can Commun Dis Rep. 2002;28:1-32.
3. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J. 2000;19:388-393.
4. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J. 1999;18:543-551.
5. 197 in United States infants. Pediatrics. 1998;101:604-611.
6. 197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18:757-763.
7. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
8. King JC, Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine. 1998;16:361-365.
9. Scheifele DW, Guasparini R, Lavigne P. A comparative study of PENTA™ vaccine booster doses given at 12, 15 or 18 months of age. Vaccine. 1999;17:543-550.
10. Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001;19:3331-3346.
11. Scheifele DW, Halperin SA, Smith B, et al. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP. IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine. 2006;24:2057-2064.
12. Reference deleted in proof.
13. Black S, Shinefield H, Baxter R, et al. Post-licensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-489.
14. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends in invasive disease due to Streptococcus pneumoniae among children in the Intermountain West: emergence of non-vaccine groups. Clin Infect Dis. 2005;41:21-29.
15. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
16. Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D. Progress in the prevention of pneumococcal infection. Can Med Assoc J. 2005;173:1149-1151.
17. Soininen A, Pursiainen H, Kilpi T, Kayhty H. Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J Infect Dis. 2001;184:569-576.
18. Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anti-capsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367-376.
19. Jones VF, Harrison C, Stout GG, Hopkins J. Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr Infect Dis J. 2005;24:969-973.